What is the market's earnings forecast for AbCellera Biologics next quarter?

What factors drove the changes in AbCellera Biologics's revenue and profit?

What is AbCellera Biologics's latest dividend and current dividend yield?

What does AbCellera Biologics do and what are its main business segments?

What is AbCellera Biologics's gross profit margin?

What guidance did AbCellera Biologics's management provide for the next earnings period?

Did AbCellera Biologics beat or miss consensus estimates last quarter?

What were the key takeaways from AbCellera Biologics's earnings call?

- **Clinical Momentum**: Phase I trials for ABCL635 and ABCL575 on track for 2026 readouts; $680M liquidity supports pipeline expansion.
- **Leadership Shift**: Dr. Sarah Noonberg appointed CMO to accelerate clinical development; Geoff Nichol departs after platform transition.
- **Revenue Transition**: Q3 revenue $9M (up 29% YoY), but R&D expenses rise to $55M as internal programs dominate focus.
- **Strategic Focus**: 103 partner programs in pipeline, with long-term value from downstream milestones; 4th internal candidate expected by year-end.
- **Competitive Position**: ABCL635 targets underserved VMS population; ABCL575 aims for 6-month dosing vs. 1-month competitors.

**【CEO Summary Section】**
- AbCellera transitioned from a platform company to a clinical-stage biotech, with Phase I trials for ABCL635 and ABCL575 progressing on track for 2026 readouts.
- Launched clinical manufacturing facility and completed platform investments, with $680 million in available liquidity.
- Appointed Dr. Sarah Noonberg as Chief Medical Officer to lead clinical pipeline development, while SVP of Development Geoff Nichol stepped down.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $9 million (vs. $7 million in Q3 2024), driven by research fees, but expected to trend lower as focus shifts to internal programs.
- R&D expenses: $55 million (up $14 million YoY), with $15 million invested in 2 internal programs.
- Net loss: $57 million (vs. $51 million YoY), with $523 million in cash and marketable securities.
- Government funding commitments: $160 million available for internal pipeline advancement.

**【Q&A Key Highlights】**
- **Partner-Initiated Programs**: 103 programs in pipeline, with clinical development lagging due to partner timelines (e.g., 6-year delay for some molecules). Long-term value expected from downstream milestones and royalties.
- **CMO Role**: Dr. Noonberg's expertise in clinical development and broad modality experience will accelerate pipeline maturation.
- **ABCL635 Data Disclosure**: Single disclosure post-proof-of-concept (mid-2026), seeking safety and efficacy comparable to fezolinetant for VMS treatment.
- **ABCL575 Enrollment**: On track, with focus on PK/half-life supporting 6-month dosing hypothesis.
- **Pipeline Progress**: On track to advance 4th internal candidate into IND-enabling studies by year-end.
- **Competitive Landscape**: ABCL635 targets 20% of women ineligible for MHT; competitors include VEOZAH and Lynkuet. ABCL575 differentiated by potential for less frequent dosing than amlitelimab.

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

- **Clinical Progress**: Initiated dosing for ABCL635 (hot flashes) Phase I trial and opened ABCL575 (atopic dermatitis) trial, advancing third program ABCL688 into IND-enabling studies.
- **Financial Strength**: $580 million cash, $750 million total liquidity, and no near-term capital constraints.
- **Pipeline Expansion**: 18 molecules in clinical development, targeting autoimmune and inflammatory diseases.
- **Strategic Focus**: Transitioning to clinical-stage biotech with internal programs; government funding supports manufacturing expansion.

**【CEO Summary Section】**
- **Clinical Milestones Achieved**: Initiated Phase I trials for ABCL635 (hot flashes) and ABCL575 (atopic dermatitis), with ABCL635 dosing underway and ABCL575 expected to begin shortly. Advanced ABCL688 into IND-enabling studies for an undisclosed autoimmune indication.
- **Pipeline Expansion**: 18 molecules now in clinical development (including partner-led programs). Aiming to advance at least one more internal program into IND-enabling studies by year-end.
- **Financial Position**: $580 million in cash and equivalents, with total liquidity of $750 million (including government funding). New manufacturing facility set to come online by end-2025.
- **2025 Priorities**: Execute Phase I trials for lead assets, advance pipeline, and bring clinical manufacturing capabilities online.

**【CFO Financial Commentary】**
- **Revenue**: Q2 2025 revenue of $17 million (vs. $7 million in Q2 2024), driven by $10 million one-time licensing fee from Trianni platform. Research fee revenue expected to trend lower as focus shifts to internal programs.
- **Net Loss**: $35 million for the quarter (vs. $37 million in Q2 2024), with R&D expenses at $39 million (flat year-over-year). Operating cash outflow of $44 million for first half of 2025.
- **Cash Management**: $460 million invested in short-term marketable securities. Capital expenditures of $36 million for GMP manufacturing and CMC infrastructure.
- **Liquidity Outlook**: Sufficient funds to execute strategy for at least the next three years, with focus on clinical trials and pipeline expansion.

**【Q&A Highlights】**
- **Regulatory Risks**: NK3R class safety concerns (liver toxicity, somnolence) may be mitigated by antibody mechanism. ABCL635 Phase I trial includes biomarker assessments (LH/FSH modulation) and POC study with 80 patients to evaluate VMS frequency/severity.
- **Market Opportunity**: 20% of menopausal women ineligible for hormone therapy, creating $1 billion+ U.S. market potential for non-hormonal VMS treatment.
- **Partnership Strategy**: Shifting focus to internal programs; one-time licensing fee not recurring. Government funding ($170 million) supports clinical manufacturing.
- **ABCL575 Development**: Phase I trial in Canada; plans to engage FDA for Phase II in U.S. OX40 ligand half-life modeling suggests potential for 6-month dosing regimen.
- **Pipeline Confidentiality**: ABCL688 details withheld until IND submission in mid-2026; program viewed as high-priority with strong preclinical validation.

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

- **ABCL635 Lead**: First-in-class NK3R antibody for menopausal hot flashes; Phase 1 starts Q3 2025, targeting $2B+ market. 
- **ABCL575 Innovation**: OX40-Ligand program with potential 3-6 month dosing; preclinical data due May 9. 
- **Financial Strength**: $630M cash, net loss $46M, ample liquidity for pipeline expansion. 
- **Clinical Milestones**: Key readouts in mid-2026 for ABCL635, Phase 1 for ABCL575 in Q3 2025. 
- **TCE Platform**: Diversified approach to T-cell engagers; early data expected to inform development strategy.

**【CEO Summary Section】**
- **ABCL635 Program Update**: Targeting NK3R for moderate-to-severe menopausal hot flashes (VMS). Phase 1 clinical trial expected to start Q3 2025, with safety and efficacy readouts in mid-2026. Market potential exceeds $2 billion annually. 
- **ABCL575 Program Progress**: CTA filing in Q2 2025, Phase 1 trial to begin Q3. Preclinical data highlights potential for 3-6 month dosing regimen. Poster presentation at SID meeting on May 9, 2025. 
- **Pipeline Expansion**: Over 20 internal/co-development programs, with first GPCR platform-derived candidate advancing. T-cell engager (TCE) platform showing early promise in solid tumors. Clinical manufacturing facility set to launch end-2025. 

**【CFO Financial Commentary】**
- **Financial Health**: $630 million cash and equivalents, $180 million government funding available. Net loss of $46 million (Q1 2025), driven by R&D expenses ($43 million). 
- **Revenue Trends**: Q1 2025 revenue $4 million (down 60% YoY), reflecting shift to internal programs. Research fee revenue expected to continue declining. 
- **Cash Usage**: $12 million operating cash flow, $17 million capital expenditures (GMP facility). Total liquidity $810 million, sufficient for >3 years of pipeline investment. 

**【Q&A Highlights】**
- **ABCL635 Clinical Design**: Phase 1 will assess safety, NK3R engagement (testosterone levels), and early efficacy in healthy volunteers. Differentiation via monthly dosing vs. daily small molecules. 
- **ABCL575 Dosing Expectations**: Preclinical data supports 3-6 month dosing. Poster presentation to detail PK predictions. 
- **Manufacturing Strategy**: No immediate plans for U.S. redundancies; Canadian facility adequate for clinical supply. 
- **IP Considerations**: Canadian IP jurisdiction remains favorable; no current plans to spin off assets. 
- **TCE Platform Outlook**: Multiple formats under evaluation; potential for internal development or partnerships. Early efficacy/safety data expected in 2026.

AbCellera Biologics (ABCL)-8 May 25-2025 Q1 Earnings call transcript

- **Strategic Shift Complete**: $800M+ liquidity enables clinical-stage biotech transition, with 2 lead programs entering clinic in 2025
- **Pipeline Momentum**: 20+ preclinical programs, including first-in-class metabolic candidate and OX40 antagonist with $10B+ market potential
- **Financial Strength**: $650M cash, 2025 cash usage manageable at ~$150M/year
- **Partnership Pivot**: Reduced discovery partnerships, focused on high-value TCE collaborations
- **Clinical Readiness**: Teams and manufacturing facility set to support 2025 Phase 1 starts

**【CEO Strategic Overview】**
- Transitioned from platform/partnership model to clinical-stage biotech, completing $800M+ liquidity build.
- 2024 milestones: 2 programs (ABCL635, ABCL575) on track for Q2 2025 CTA filings; new clinical manufacturing facility set to launch Q4 2025.
- 2025 priorities: 
  1. Initiate Phase 1 trials for lead candidates
  2. Nominate 2+ new development candidates/year
  3. Finalize platform investments by Q2 2025
  4. Expand internal pipeline across 20+ preclinical programs

**【Key Pipeline Details】**
- **ABCL635**: Metabolic/endocrine target with $2B+ TAM, potential first-in-class antibody therapy. Phase 1 data expected H2 2025.
- **ABCL575**: OX40 ligand antagonist for autoimmune diseases, with $10B+ atopic dermatitis market. Q2 2025 CTA submission, Phase 1 readouts Q2 2026.

**【Partnership Strategy】**
- Reduced new discovery partnerships (2 in H1 2024 vs. 19 in 2023), focusing on high-value collaborations:
  - 96 partner-initiated programs with downstream participation (16 in clinic)
  - 27 AbCellera-initiated programs in human health
- New TCE collaboration with AbbVie leverages internal platform strength, with potential for multi-target expansion.

**【CFO Financial Highlights】**
- 2024 cash position: $650M (cash + marketable securities) + $190M government funding commitments
- Revenue: $29M (down 24% YoY) due to shift to internal programs
- R&D expenses: $167M (down 5% YoY), driven by platform investments
- Net loss: $163M (vs. $146M YoY), including $47M in-process R&D impairment
- 2025 cash usage: ~$110M operating + $40M PP&E investments

**【Q&A Key Takeaways】**
- Clinical trial expertise being built programmatically, with teams scaled to support lead candidates
- TCE platform differentiation through diverse CD3 library and high-throughput screening
- Government tariffs on U.S. imports exempt for biomanufacturing supplies
- Open to partnering for later-stage programs, e.g., ABCL575 for multi-indication development

Actual	0.44	0.37	-0.01	-0.08	0.19	0.54	-0.02	0.08	-0.1	-0.14	-0.11	-0.1	-0.16	-0.14	-0.13	-0.17	-0.12	-0.15	-0.12	-0.19	-0.03
Forecast	0.6333	0.36	0.0825	-0.035	0.2039	0.3985	0.003	0.0627	0.0097	-0.1286	-0.1343	-0.1211	-0.1149	-0.1255	-0.12	-0.1244	-0.1333	-0.1361	-0.1342	-0.1388	-0.134
Surprise	-30.52%	+2.78%	-112.12%	-128.57%	-6.82%	+35.51%	-766.67%	+27.59%	-1130.93%	-8.86%	+18.09%	+17.42%	-39.25%	-11.55%	-8.33%	-36.66%	+9.98%	-10.21%	+10.58%	-36.89%	+77.61%

ABCL

ABCL fundamentals

ABCL Q4 2025 Earnings

Earnings Call

You can ask Aime

ABCL

ABCL fundamentals

ABCL Q4 2025 Earnings

Earnings Call

ABCL Earnings Call Summary for Q4/20255:00 PM on Feb 24, 2026

ABCL Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

ABCL Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

ABCL Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

ABCL Earnings Call Summary for Q4/20245:00 PM on Feb 27, 2025

You can ask Aime